/LSTA
LSTA Stock - Lisata Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.06+2.49%
+$0.05 (+2.49%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.27
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LSTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.04 – $2.08
TARGET (TP)$2.37
STOP LOSS$1.90
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.09
52W High$4.20
52W Low$1.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.00M | N/A | N/A | N/A | N/A |
| Gross Profit | $1.00M | N/A | N/A | N/A | $-63,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-22,409,000 | $-25,708,000 | $-57,601,000 | $-29,050,000 | $-19,145,000 |
| Net Income | $-19,985,000 | $-20,840,000 | $-54,225,000 | $-27,466,000 | $-8,150,000 |
| Net Margin | -1998.5% | N/A | N/A | N/A | N/A |
| EPS | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-7.91 |
Company Overview
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LSTABeat Rate
83%
Last 18 quarters
Avg Surprise
+13.0%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-0.49
Q4 2025
EPS Surprise History
Q1 24
+23.3%
$-0.66vs$-0.86
Q2 24
+11.0%
$-0.65vs$-0.73
Q3 24
+18.7%
$-0.61vs$-0.75
Q4 24
+21.3%
$-0.59vs$-0.75
Q1 25
+27.6%
$-0.55vs$-0.76
Q2 25
-3.8%
$-0.55vs$-0.53
Q3 25
+16.9%
$-0.54vs$-0.65
Q4 25
+9.3%
$-0.49vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.51 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.54 | $-0.49 | +9.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.65 | $-0.54 | +16.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.53 | $-0.55 | -3.8% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.76 | $-0.55 | +27.6% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.75 | $-0.59 | +21.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.75 | $-0.61 | +18.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.73 | $-0.65 | +11.0% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.86 | $-0.66 | +23.3% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.93 | $-0.65 | +30.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.70 | $-0.50 | +28.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.81 | $-0.77 | +4.9% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.96 | $-0.76 | +20.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.90 | $-1.47 | -63.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.45 | $-1.65 | -13.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.45 | $-1.05 | +27.6% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-2.17 | $-1.65 | +24.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-2.25 | $-1.80 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-2.17 | $-1.50 | +30.9% | ✓ BEAT |
Latest News
Lisata Therapeutics Q3 EPS $(0.49) Beats $(0.61) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:10 PM
Lisata Therapeutics Releases Preclinical Data Showing That Lisata's Proprietary iRGD Cyclic Peptide, Certepetide, And Its Analogs Enhanced The Efficacy And Tumor Distribution Of Catalent's Smartag Antibody-Drug Conjugate Platform
📈 PositiveBenzinga•Nov 4, 2025, 09:03 PM•Also:
Lisata Therapeutics And Catalent Enters Global Antibody-Drug Conjugate License Agreement. Lisata Therapeutics To Receive Over $10M In Milestone Payments
📈 PositiveBenzinga•Oct 8, 2025, 12:35 PM•Also:
Lisata Therapeutics Releseass Preliminary Results From Pancreatic Ductal Adenocarcinoma Cohort In Phase 1/2a CENDIFOX Trial Showing Certepetide Can Enhance The Effectiveness Of Standard-Of-Care Chemotherapy In Pancreatic Cancer
📈 PositiveBenzinga•Sep 29, 2025, 12:06 PM
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Aug 21, 2025, 11:18 AM
Frequently Asked Questions about LSTA
What is LSTA's current stock price?
Lisata Therapeutics, Inc. (LSTA) is currently trading at $2.06 per share. The stock has moved +2.49% today.
What is the analyst price target for LSTA?
No analyst price targets are currently available for this stock.
What sector is Lisata Therapeutics, Inc. in?
Lisata Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LSTA's market cap?
Lisata Therapeutics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does LSTA pay dividends?
No, Lisata Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NCNA
NuCana plc
$3.56
Mkt Cap: $0.0B
PASG
Passage Bio, Inc.
$9.59
Mkt Cap: $0.0B
PTHS
Pelthos Therapeutics Inc.
$25.63
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to LSTA for comparison